Hepatocellular carcinoma
Scientific Reports in Medicine · 2024
DOI: 10.37609/srinmed.15 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports in Medicine, 2024. Verfasst von Mehmet Mutlu Kidi. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a primary liver cancer predominantly arising in individuals with chronic liver diseases such as cirrhosis or chronic hepatitis B virus (HBV) infection. Accounting for approximately 75% of primary liver tumors, HCC's global epidemiology is significantly influenced by HBV and hepatitis C virus (HCV) infections, alcohol and tobacco use, metabolic syndrome, diabetes, obesity, and aflatoxin B1 exposure. Preventive measures, including HBV vaccination and direct-acting antivirals for HCV, have reduced incidence rates, particularly in younger populations. Early diagnosis through surveillance in high-risk groups is critical, employing imaging modalities like ultrasound, CT, and MRI, alongside biomarkers such as alpha-fetoprotein (AFP). Prognostic assessments utilize scores like Child-Pugh and ALBI. Treatment strategies for HCC are multifaceted, involving surgical resection, locoregional therapies (e.g., transarterial chemoembolization), and systemic therapies, including targeted and immunotherapies. Despite advancements, treatment efficacy remains a challenge, necessitating ongoing research into novel therapeutic approaches and predictive biomarkers to enhance personalized treatment and improve outcomes for HCC patients.
Zitieren
APA
Kidi, M. M. (2024). Hepatocellular carcinoma. Scientific Reports in Medicine. https://doi.org/10.37609/srinmed.15
Vancouver
Kidi MM. Hepatocellular carcinoma. Scientific Reports in Medicine. 2024. doi:10.37609/srinmed.15
BibTeX
@article{Kidi2024,
author = {Kidi, Mehmet Mutlu},
title = {Hepatocellular carcinoma},
journal = {Scientific Reports in Medicine},
year = {2024},
doi = {10.37609/srinmed.15}
}
EUVIMED